Summit Therapeutics (NASDAQ:SMMT) and Purple Biotech (NASDAQ:PPBT) Head-To-Head Survey

Summit Therapeutics (NASDAQ:SMMT) and Purple Biotech (NASDAQ:PPBT) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Profitability

This table compares Summit Therapeutics and Purple Biotech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-168.94%	-141.92%
Purple Biotech	N/A	-123.63%	-98.72%

Insider and Institutional Ownership

4.6% of Summit Therapeutics shares are held by institutional investors. Comparatively, 9.6% of Purple Biotech shares are held by institutional investors. 83.5% of Summit Therapeutics shares are held by company insiders. Comparatively, 3.0% of Purple Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Summit Therapeutics and Purple Biotech, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	2	6	7	1	2.44
Purple Biotech	1	1	1	0	2.00

Summit Therapeutics currently has a consensus price target of $26.15, indicating a potential upside of 87.96%. Purple Biotech has a consensus price target of $30.00, indicating a potential upside of 1,971.82%. Given Purple Biotech’s higher probable upside, analysts clearly believe Purple Biotech is more favorable than Summit Therapeutics.

Earnings & Valuation

This table compares Summit Therapeutics and Purple Biotech”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08 billion	($1.12)	-12.42
Purple Biotech	N/A	N/A	-$26.39 million	($18.84)	-0.08

Summit Therapeutics is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Summit Therapeutics has a beta of -1.26, suggesting that its share price is 226% less volatile than the S&P 500. Comparatively, Purple Biotech has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500.

Summary

Purple Biotech beats Summit Therapeutics on 7 of the 12 factors compared between the two stocks.

About Summit Therapeutics

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company’s lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

About Purple Biotech

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.